Kikuchi Satoru, Honda Kazufumi, Tsuda Hitoshi, Hiraoka Nobuyoshi, Imoto Issei, Kosuge Tomoo, Umaki Tomoko, Onozato Kaoru, Shitashige Miki, Yamaguchi Umio, Ono Masaya, Tsuchida Akihiko, Aoki Tatsuya, Inazawa Johji, Hirohashi Setsuo, Yamada Tesshi
Chemotherapy Division, Cancer Proteomics Project, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan.
Clin Cancer Res. 2008 Sep 1;14(17):5348-56. doi: 10.1158/1078-0432.CCR-08-0075.
An invasive growth pattern is one of the hallmarks of pancreatic ductal carcinoma. Actinin-4 is an actin-binding protein associated with enhanced cell motility, invasive growth, and lymph node metastasis. Actinin-4 might play an important role in the development and progression of pancreatic cancer.
The expression of actinin-4 was examined immunohistochemically in 173 cases of invasive pancreatic ductal carcinoma. The copy number of the actinin-4 (ACTN4) gene was calculated by fluorescence in situ hybridization. The expression of actinin-4 was stably knocked down by short hairpin RNA, and tumorigenicity was evaluated by orthotopic implantation into mice with severe combined immunodeficiency.
The expression level of actinin-4 was increased in 109 (63.0%) of 173 cases of pancreatic cancer. Kaplan-Meier survival curves revealed that patients with increased expression of actinin-4 had a significantly poorer outcome (P=0.00001, log-rank test). Multivariate analysis by the Cox proportional hazard model showed that high expression of actinin-4 was the most significant independent negative predictor of survival (hazard ratio, 2.33; P=0.000009). Amplification (defined as more than four copies per interphase nucleus) of the ACTN4 gene was detected in 11 (37.9%) of 29 cases showing increased expression of actinin-4. Knockdown of actinin-4 expression inhibited the destructive growth of cancer cells in the pancreatic parenchyma.
Recurrent amplification of chromosome 19q13.1-2 has been reported in pancreatic cancer, but the exact target gene has not been identified. Actinin-4 contributes to the invasive growth of pancreatic ductal carcinoma, and ACTN4 is one of the candidate oncogenes in this chromosome locus.
侵袭性生长模式是胰腺导管癌的特征之一。辅肌动蛋白4是一种与细胞运动性增强、侵袭性生长及淋巴结转移相关的肌动蛋白结合蛋白。辅肌动蛋白4可能在胰腺癌的发生发展中起重要作用。
采用免疫组织化学方法检测173例侵袭性胰腺导管癌中辅肌动蛋白4的表达。通过荧光原位杂交计算辅肌动蛋白4(ACTN4)基因的拷贝数。利用短发夹RNA稳定敲低辅肌动蛋白4的表达,并通过原位植入严重联合免疫缺陷小鼠评估其致瘤性。
173例胰腺癌中有109例(63.0%)辅肌动蛋白4表达水平升高。Kaplan-Meier生存曲线显示,辅肌动蛋白4表达升高的患者预后明显较差(P=0.00001,对数秩检验)。Cox比例风险模型多因素分析表明,辅肌动蛋白4高表达是生存的最显著独立负性预测因子(风险比,2.33;P=0.000009)。在29例辅肌动蛋白4表达升高的病例中,有11例(37.9%)检测到ACTN4基因扩增(定义为每个间期核多于4个拷贝)。敲低辅肌动蛋白4表达可抑制胰腺实质中癌细胞的侵袭性生长。
胰腺癌中已报道19q13.1-2染色体反复扩增,但确切的靶基因尚未确定。辅肌动蛋白4促进胰腺导管癌的侵袭性生长,ACTN4是该染色体位点的候选癌基因之一。